Femoropopliteal articles

Programas de ejercicios en la enfermedad vascular periférica

Discrepancy between Angina and Ischemia Repeats in Peripheral Artery Disease

Discrepancy between Angina and Ischemia Repeats in Peripheral Artery Disease

Three randomized studies showed exercising significantly improves 6-minute walk outcomes in patients with peripheral artery disease (PAD). However, many participants randomized to exercise did not perceive changes, and sometimes even got worse.  These findings suggest a significant discrepancy between objective and perceived change in walking ability among PAD patients.   400 patients with peripheral artery disease

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

ELUVIA: DES in Complex Femoropopliteal Lesions

Paclitaxel-eluting stent Eluvia showed promising results after two years with a revascularization freedom rate of 80% despite the fact that these were complex femoropopliteal lesions. As the safety of paclitaxel-eluting devices becomes more consistent, more studies on its efficacy are being published. Back in 2018, the safety of paclitaxel-eluting balloons and stents was under scrutiny

SAFE-PAD: Dispositivos liberadores de paclitaxel en enfermedad periférica

ACC 2021 | SAFE-PAD: Paclitaxel-Eluting Devices in Peripheral Disease

This work was conducted alongside the US Food and Drug Administration (FDA) to investigate the association between all-cause mortality and paclitaxel-eluting devices in peripheral vascular disease. According to data from SAFE-PAD, presented at the American College of Cardiology (ACC) 2021 Congress and simultaneously published in JAMA, there is no increase in mortality compared with conventional

SOLACI PERIPHERAL | Common, superficial and deep femoral artery recanalization

SOLACI PERIPHERAL | 6th Clinical Case: Common, Superficial and Deep Femoral Artery Recanalization

Here is a new SOLACI PERIPHERAL Case! In this opportunity, Dr. Ana Paula Mollón (Arg.) presents “Common, Superficial and Deep Femoral Artery Recanalization”. This is the 6th clinical case presented by SOLACI Peripheral. The purpose of this space is to encourage and further the exchange of experiences and opinions, to keep advancing our knowledge in

Subutilización del tratamiento médico en enfermedad vascular periférica

Optimal Medical Treatment Under-used in Vascular Peripheral Disease

Less than half of patients undergoing endovascular revascularization for peripheral artery disease to their lower limbs are discharged with optimal medical treatment.  Their traditional risk factors are predictors of a more comprehensive treatment; however, women, patients with higher risk of thrombosis, and those more likely to lose a lower limb, are far from being treated

Diabetes y enfermedad vascular periférica: viejas drogas con nueva evidencia

Diabetes and Peripheral Vascular Disease: Old Drugs, New Evidence

This paper, recently published in JAHA, showed that patients with type 2 diabetes mellitus exhibiting lower-limb vascular disease benefit from combining cilostazol and clopidogrel. Treatment for at least 6 months with clopidogrel (75 mg/QD) plus cilostazol (100 mg/BID) significantly reduces ischemic events—including stroke, infarction, and death from vascular causes—compared with clopidogrel monotherapy. Adding cilostazol reduces ischemic events, but that

Continuar con la actividad física luego de un IAM reduce la mortalidad

The Key We Are Overlooking in Peripheral Vascular Disease

To change the prognosis of peripheral vascular disease patients, a referral for supervised exercise is paramount. This should be a cultural change, not only an individual recommendation. A physically active lifestyle reduces the risk of cardiovascular events and functional impairment in patients with peripheral vascular disease. The novelty of this work (forthcoming in Eur J

ESC 2020 | El Rivaroxaban puede reducir los eventos cardíacos, cerebrales y periféricos

ESC 2020 | Rivaroxaban Might Reduce Cardiac Cerebral and Peripheral Events

Adding rivaroxaban to the standard treatment might reduce events incidence in lower limbs, heart, and brain, in patients with peripheral vascular disease undergoing revascularization.   These new data resulted from the analysis of the VOYAGER PAD subgroups and were presented at the virtual ESC 2020. The COMPASS study had reached similar conclusions using 2.5 mg rivaroxaban

Nuevas estrategias en el territorio femoropoplíteo

Common Femoral Artery Endarterectomy Plus Angioplasty in Critical Ischemia

This prospective study analyzed patients with critical lower limb ischemia (due to complex, multiple lesions in several places) who were treated uniformly with common femoral artery endarterectomy combined with angioplasty to improve inflow and/or outflow. This hybrid treatment, which must be carried out by a team, can be greatly beneficial for this high-risk patient group

Virtual ACC 2020 | VOYAGER PAD: Rivaroxaban Superior to Aspirin in Preventing Events

In patients with peripheral artery disease undergoing revascularization, the combination of rivaroxaban (Xarelto) and low doses of aspirin are superior to aspirin alone in the prevention of acute low limb ischemic events, amputation, cardiovascular events and strokes. The outcomes of VOYAGER PAD add to the COMPASS outcomes, showing the combination of therapies can benefit risk

ACC 2020 Virtual | Sub-análisis del COMPASS: la diabetes aumenta el beneficio del rivaroxaban más AAS

Virtual ACC 2020 | COMPASS Sub-Analysis: Diabetes Increases the Benefit of Rivaroxaban Combined with AAS

In patients with stable coronary or peripheral artery disease, diabetes increases the benefit of combining low doses of rivaroxaban and aspirin vs. aspirin alone.  This analysis was pre-specified in the COMPASS protocol and was presented virtually for the ACC 2020 and simultaneously published in Circulation. Patients with diabetes, showed numerically greater reduction in terms of